NEW
Cresemba

Cresemba Caution For Usage

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Full Prescribing Info
Caution For Usage
Incompatibilities: Cap: Not applicable.
Inj: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in the following text.
Special precautions for disposal and other handling: Reconstitution: One vial of the powder for concentrate for solution for infusion should be reconstituted by addition of 5 mL water for injections to the vial. The vial should be shaken to dissolve the powder completely. The reconstituted solution should be inspected visually for particulate matter and discoloration. Reconstituted concentrate should be clear and free of visible particulate. It must be further diluted prior to administration.
Dilution and administration: After reconstitution, the entire content of the reconstituted concentrate should be removed from the vial and added to an infusion bag containing at least 250 mL of either sodium chloride 9 mg/mL (0.9%) solution for injection or 50 mg/mL (5%) dextrose solution. The infusion solution contains approximately 1.5 mg/mL isavuconazonium sulfate (corresponding to approximately 0.8 mg isavuconazole per mL). After the reconstituted concentrate is further diluted, the diluted solution may show fine white-to-translucent particulates of isavuconazole, that do not sediment (but will be removed by in-line filtration). The diluted solution should be mixed gently, or the bag should be rolled to minimise the formation of particulates. Unnecessary vibration or vigorous shaking of the solution should be avoided. The solution for infusion must be administered via an infusion set with an in-line filter (pore size 0.2 μm to 1.2 μm) made of polyether sulfone (PES).
Isavuconazole should not be infused into the same line or cannula concomitantly with other intravenous products.
Storage conditions after reconstitution and dilution are provided in Storage.
If possible, the intravenous administration of isavuconazole should be completed within 6 hours after reconstitution and dilution at 15°C to 25°C. If this is not possible, the infusion solution should be immediately refrigerated after dilution, and infusion should be completed within 24 hours. Further information regarding the storage conditions after reconstitution and dilution of the medicinal product is provided in Storage.
An existing intravenous line should be flushed with sodium chloride 9 mg/mL (0.9%) solution for injection or 50 mg/mL (5%) dextrose solution.
This medicinal product is for single use only. Discard partially-used vials.
This medicinal product may pose a risk to the environment (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in